Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells‐based therapy product

Induced pluripotent stem cells (iPSC)‐based therapies have been hailed as the future of regenerative medicine because of their potential to provide treatment options for most degenerative diseases. A key promise of iPSC‐based therapies is the possibility of an autologous transplant that may engraft...

Descripción completa

Detalles Bibliográficos
Autores principales: Jha, Balendu Shekhar, Farnoodian, Mitra, Bharti, Kapil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Concise Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848308/
https://www.ncbi.nlm.nih.gov/pubmed/32946199
http://dx.doi.org/10.1002/sctm.20-0242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848308/
https://www.ncbi.nlm.nih.gov/pubmed/32946199
http://dx.doi.org/10.1002/sctm.20-0242

Ejemplares similares